The demo realized the two its Key endpoints, with semaglutide 2.4 mg demonstrating statistically sizeable and exceptional enhancements in liver fibrosis without worsening of steatohepatitis, in addition to resolution of steatohepatitis without worsening of liver fibrosis in individuals with MASH com